上海睿昂基因科技股份有限公司2025年度业绩快报公告

Financial Performance Summary - In 2025, the company reported total operating revenue of 173.9999 million yuan, a decrease of 28.19% compared to the previous year [3] - The operating profit was -53.5036 million yuan, with a loss increase of 2.50818 million yuan year-on-year [3] - The total profit amounted to -54.4323 million yuan, reflecting a loss increase of 2.59578 million yuan compared to the previous year [3] - The net profit attributable to the parent company was -49.8836 million yuan, with a loss increase of 3.41191 million yuan year-on-year [3] - The basic earnings per share were -0.90 yuan, indicating a loss increase of 0.62 yuan compared to the previous year [3] Factors Affecting Performance - The decline in operating revenue was primarily due to intensified competition in the in vitro diagnostic industry and specific events affecting the company [4] - The slower payment collection from downstream clients, influenced by the medical industry environment, led to the recognition of credit impairment losses on accounts receivable [4] - The company suspended its molecular diagnostic reagent R&D center and industrialization project, leading to impairment losses due to indications of asset impairment [4] - The performance of subsidiaries, Shanghai Yuanqi Biological and Wuhan Baitai, further declined, prompting the company to recognize goodwill impairment losses and asset impairment losses [4] Asset and Equity Status - As of the end of the reporting period, total assets were 889.6565 million yuan, a decrease of 9.74% compared to the beginning of the period [3] - The equity attributable to the parent company was 849.9908 million yuan, down 6.52% from the beginning of the period [3]